Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.
The most advanced candidate discovered by our IND engine is cabiralizumab (also known as FPA008), an investigational antibody that inhibits the colony stimulating factor-1 receptor (CSF1R) and blocks the activation and survival of macrophages.
Inhibition of CSF1R in preclinical models of several cancers reduces the number of immunosuppressive tumor-associated macrophages (TAMs) in the tumor microenvironment, thereby facilitating an immune response against tumors.
Cabiralizumab is currently in clinical trials in oncology indications.
In October 2015, we announced an exclusive worldwide license and collaboration agreement with BMS for the development and commercialization of cabiralizumab, with an option to co-promote cabiralizumab in the United States.